Abstract
Introduction
The growing epidemic of obesity in the last decade has drawn the attention on the sleep apnea syndrome as a cardiovascular risk factor. Obstructive sleep apnea (OSA) syndrome represents a frequent pathology, closely related with cardiovascular diseases, especially heart failure and hypertension [1] , but it is often unrecognized. The overlap between type 2 diabetes mellitus (T2DM) and sleep apnea was first described few decades ago [2] . A possible explanation of this association is the presence of shared risk factors such as obesity, visceral adiposity and advancing age. Still, the presence of metabolic or autonomic abnormalities associated with one that could influence the development of the other cannot be excluded [3] . Furthermore, a growing number of studies have suggested that the relationship between T2DM and OSA is independent of the degree of obesity [4] [5] [6] [7] [8] [9] . Irrespective of the independence of this relationship, the observed association of sleep apnea syndrome (SAS) with type 2 diabetes has important clinical, epidemiological and public health implications [10] 
Type 2 diabetes and OSApathogenetic mechanisms
Several mechanisms have been proposed to explain the interaction between OSA and T2DM ( Figure 1 
Prevalence of OSA in patients with type 2 diabetes
If in general population, the prevalence of SAS is 3-7% in men and 2-5% in women [1] , in patients with T2DM it varies from 23 to 80% [17] [18] [19] [20] . These discrepancies in the reported prevalence of OSA in patients with T2DM are attributable to both screening methods used in epidemiological studies and inclusion of highly selected population (only males or patients with a BMI>35kg/m 2 . Simptoms of daytime sleepiness, snoring, neck circumference and hypertension were assessed using Berlin questionnaire in 1676 men with T2DM. The response to this questionnaire was used to classify participants as having a low or a high risk for sleep apnea. In a second stage, a percent of patients from both groups were evaluated by overnight oxymetry and the results were verified by detailed sleep studies. This study reported a prevalence of OSA of 23%. Also, the authours identified BMI as significant independent predictor of OSA in this population [17] .
Other 4 studies that included a total of 1300 patients with T2DM reported a prevalence of SAS between 53.9 and 86%. In all above mentioned researches the screening and diagnosis of SAS was based on overnight polysomnography, which is considered the "gold standard" for the diagnosis of sleep apnea [16, 18, 
Prevalence and incidence of T2DM in OSA
A growing number of observational and experimental studies from different geographical regions and involving various populations suggests the existence of a relationship between impaired glucose metabolism and OSA. Although, there have been two decades since researchers studied metabolic consequences of OSA, the results were contradictory [28] . We will present below the most important results regarding this aspect.
In 2003 Meslier and collaborators published the results of a cross-sectional study that aimed to evaluate the prevalence of T2DM and impaired glucose tolerance (IGT) in a large clinic-based male population (n=595) presenting various degrees of obstructive sleep apnea syndrome and to analyse the relationship between OSA and glucose-insulin metabolism [29] . Prevalence of T2DM was significantly higher in patients with OSA compared with non-apnoeic patients (30.1% vs. 13.9%). Additionally, authors concluded that in this clinical-based sample fasting and postload blood glucose increased and insulin sensitivity decreased with severity of sleep apnea, and the observed relationship between sleep-disordered breathing and impaired glucose-insulin metabolism was independent of obesity and age [29] .
The most valuable evidence regarding the association between sleep apnea and diabetes is provided by Sleep Heart Health Study, a landmark trial in somnology. In a subset of participants (2656 persons) OSA diagnosis was based on an unattended polysomnography conducted in each participant's home. Fasting and 2-hour glucose levels measured during an oral glucose tolerance test were used to assess glycemic status [30] . Increased severity of OSA (as assessed by respiratory disturbance index -RDI) was associated with higher odds of impaired fasting glucose and impaired glucose tolerance after adjustment for several confounding covariates, including age, gender, smoking status, body mass index, waist circumference, and self-reported sleep duration (HR: 1.46; 95% CI: 1.09-1.97) [30] . The severity of sleep-disordered breathing, as assessed by the RDI, was also found to be independently associated with degree of insulin resistance [30] .
The Wisconsin Sleep Study is the largest prospective trial that evaluated the prevalence and the incidence of T2DM in 1387 patients with sleep apnea followed for 4 years [31]. In the cross-sectional analysis of baseline data there was a greater prevalence of diabetes with increasing severity of OSA independent of age, sex and waist circumference (14.7% of subjects with an AHI of 15 or more had a diagnosis of diabetes compared with 2.8% of subjects with an AHI of less than 5). However, these results were not confirmed by the longitudinal analysis: after adjusting for shared risk factors, incidence of diabetes over a 4 years follow-up period was not significantly related to the severity of SDB at the time of initial enrollment in the cohort (OR:1.62; 95% CI, 0.67-3.65; p = 0.24) [31] .
Impact of OSA on glycemic control in patients with type 2 diabetes
Aronsohn and collaborators have recently published a research that evaluated the effect of OSA on HbA1c (as a measure of glycemic control) in 60 patients with type 2 diabetes [21] . The authors demonstrated that incresing severity of OSA was associated with poorer glycemic control, after adjusting for age, sex, race, BMI, number of diabetes medications, level of exercise, years of diabetes and total sleep time. Compared to patients without OSA, the adjusted mean HbA1c was increased by 1.49% in patients with mild OSA (p=0.002), 1.93% in patients with moderate OSA (p=0.003), and 3.69% in patients with severe OSA (p<0.0001).
The results published by Aronshon et al are in contradiction with those from an earlier study that involved 279 patients and did not report any association between OSA and HbA1c [32] . The negative results could be explained by the duration of sleep recording (ranging from 4 hours) and could be also due to the fact that only 22% in the population performed a full polysomnography. In contrast, Aronsohn et all included in analysis only patients with sleep recording duration over 7 hours and performed an additional analysis which showed that if in analysis would be used only the first 4 hours of polysomnography the association between OSA and HbA1c was no longer visible [21] .
CPAP treatment and glucose metabolism
If we think about the mechanism involved in the association OSA-glucose metabolism, it can be hypothesised that treatment of sleep apnea could impact insulin resistance and improve glucose metabolism. Studies with OSA patients, with or without diabetes, which have investigated the impact of CPAP therapy regarding insulin-sensitivity and glucose metabolism have shown heterogeneous results. These contradictory results could be explained by the absence of the control group, low statistical power, difference in length of follow up or the absence of data regarding CPAP compliance [14] .
Several uncontrolled interventional studies evaluated the impact of CPAP therapy on insulin resistance or glucose metabolism in patients with or without T2DM. The largest uncontrolled interventional study that documents the benefficial effect of CPAP therapy on insulin sensitivity (evaluated by hyperinsulinemic, euglycemic clamp) included 40 non-diabetic patients [33] . Insulin sensitivity significantly increased after 2 days of CPAP therapy (5.75±4.20 baseline versus 6.79±4.91 μmol/kg · min; p=0.003) and remained stable after 3 months of treatment. The improvement in insulin sensitivity after 2 days was much greater in patients with a BMI <30kg/m 2 compared with patients with BMI ≥30kg/m 2 [33] .
Recently a small number of trials that included diabetic patients with OSA evaluated the effect of CPAP therapy on glycemic control assessed by HbA1c and continuous glucose monitoring (Table 1) . The earlier two studies included a total of 19 patients and reported improvment in insulin sensitivity after 3-4 months of treatment, but with no effect on HbA1c levels [33, 34] 
